Does insurance cover screening Breast Magnetic Resonance Imaging (MRI) for high-risk patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: May 28, 2025 • View editorial policy

From the Guidelines

Insurance typically covers screening breast MRI for high-risk patients, though coverage varies by insurer and specific risk factors. Most private insurance plans, Medicare, and Medicaid cover annual screening breast MRIs for women with a lifetime breast cancer risk of 20% or greater, those with BRCA1 or BRCA2 gene mutations, or those with a history of chest radiation between ages 10-30 1, 2. Coverage may also extend to women with personal histories of breast cancer, certain genetic syndromes, or strong family histories of breast or ovarian cancer.

Key Points to Consider

  • The American College of Radiology recommends annual breast MRI in high-risk women beginning as early as 25 years of age 2.
  • The American Cancer Society has recommended annual breast MRI for breast cancer screening in high-risk women since 2007 3.
  • Breast MRI has a higher sensitivity in detecting cancers in dense breast tissue and high-risk populations compared to mammography alone, allowing for earlier detection and potentially better outcomes in these specific groups 1, 2. However, patients should verify coverage with their specific insurance provider before scheduling, as some plans may require prior authorization, have specific network requirements, or impose higher copayments or deductibles for MRI screenings.

Important Considerations

  • Insurance companies base their coverage decisions on clinical guidelines that recognize breast MRI's superior sensitivity in detecting cancers in dense breast tissue and high-risk populations compared to mammography alone 1, 2.
  • The incremental cancer detection rate of MRI in elevated-risk women ranges from 8 to 29 per 1,000 women, with higher detection rates in BRCA mutation carriers 2.

From the Research

Insurance Coverage for Screening Breast MRI

  • Insurance coverage for screening breast MRI in high-risk patients is not consistently guaranteed, as evidenced by studies showing denial rates for breast MRI screening in women with germline BRCA1/2 mutations 4.
  • A study found that 11% of women with germline BRCA1/2 mutations had their breast MRI screening denied by insurance, with Medicaid-insured women having the highest denial rates 4.
  • Despite the existence of guidelines recommending annual breast MRI screening for high-risk women, insurance denials can create barriers to early detection 4.

Effectiveness of Breast MRI Screening

  • Breast MRI has been shown to be more sensitive than mammography, ultrasound, and clinical breast examination in detecting breast cancers in BRCA1 and BRCA2 mutation carriers 5.
  • A comparative effectiveness analysis found that alternating digital mammography and MRI at 6-month intervals starting at age 25 provided the highest life expectancy for BRCA1 and BRCA2 mutation carriers 6.
  • Another study found that MRI detected cancers that were not identified on mammography 6 months earlier in women with genetically high risk of developing breast cancer 7.

Screening Strategies

  • Different screening strategies, including annual screening with mammography and MRI, alternating mammography and MRI, and MRI alone, have been compared in terms of their effectiveness in detecting breast cancer in high-risk women 6.
  • The choice of screening strategy should consider the benefits, risks, and personal acceptance of false-positive results for individual women 6.
  • A study found that the cancer prevalence was highest for staging contralateral invasive lobular carcinoma, followed by high-risk screening and surveillance 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.